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Abstract
Background The purpose of the present study was to
analyze long-term survival and disease-free survival after
liver resection for giant hepatocellular carcinoma
(HCC) C 10 cm compared to HCC \ 10 cm in diameter.
The surgical approach in the treatment of giant HCC may
achieve long-term survival and disease-free survival com-
parable to treatment of smaller lesions.
Methods This retrospective analysis was a monocentric
study conducted in a tertiary university center. It included
101 patients from 114 consecutive liver resections for
HCC, separated into two groups: those with tumors less
than 10 cm in diameter (small HCC; n = 79) and those
with tumors larger than 10 cm (giant HCC; n = 22). The
main outcome measures were overall five-year survival,
five-year disease-free survival, recurrence rate, periopera-
tive mortality at 30 days, surgical complication rate, and
re-intervention rate.
Results The two groups were homogeneously distributed,
apart from cirrhosis, which was found more frequently in
the group with small HCC (77 vs. 41 %; p = 0.0013). Both
median survival (24 vs. 27 months; p = 0.0085) and
overall 5-year survival (21 vs. 45; p = 0.04) were signifi-
cantly poorer in the small HCC group compared to the
giant HCC group. There were no differences en terms of
recurrence rate, pattern, and timing.
Conclusions Liver resection for HCC larger than 10 cm
is a valuable option in selected patients, one that provides
overall survival and disease-free survival comparable to
smaller lesions. Functional reserves of the liver, more than
the size of the lesion, may be important in patient selection
for surgical resection.
Introduction
Among various factors, management guidelines for hepa-
tocellular carcinoma (HCC) rely on the size of the lesion as
a factor in selection of the most appropriate treatment. This
approach is anchored in the Milan criteria [1] for liver
transplantation and is also applied in other guidelines [2],
to determine whether liver resection (LR), radiofrequency
ablation (RFA), or transcatheter arterial chemoemboliza-
tion (TACE) should be proposed for the treatment of
individual HCC patients. The widespread use of size cri-
teria to guide HCC treatment is based, among other factors,
on the observation that both survival and risk for recur-
rence may be related to the size of the lesion [3–7], even if
this approach has not been observed in some series [8, 9].
Although the management of HCC lesions larger than
5 cm continues to be debated, few data are available
regarding giant HCC (C10 cm) [4–26], and are in most
cases retrospective. Some investigators suggest that giant
lesions represent more aggressive tumors [25] and are
associated with higher rates of vascular invasion [7], which
brings into question the value of surgery as a therapeutic
option. However, adverse outcomes have not been
observed in all studies [6, 20, 24]. Still, the lack of sig-
nificant data may lead to confusion in the choice of
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therapeutic options. For example, RFA technology and
results continue to improve, but experience with large
tumors remains limited and the few available reports are
confined to small series [25, 27–29]. Moreover, complete
ablation of large lesion remains exceptional, due to the
limitations of thermal diffusion volume and the frequent
proximity of large blood vessels, factors that inhibit the
effectiveness of RFA in these cases [30]. As consequence,
RFA is currently proposed as palliative treatment [27–29],
or is used in combination with resection [25]. Transcatheter
arterial chemoembolization has been reported to be feasible
in the treatment of giant HCC [31–34], but there are no
published reports of complete cure, thus TACE is not
validated as therapeutic approach in giant HCC. Finally,
liver resection may be the only chance of cure in these
patients [3–26], despite surgical limitations like liver size,
functional reserve, and anatomical restrictions. In fact,
radical surgery for giant HCC has been reported in some
case series, but this approach remains controversial due to
concerns regarding the potential aggressiveness of such
tumors [7, 25] the high morbidity associated with major
liver interventions—25 % to more than 50 % in recent
series [4, 16–19, 23, 26]—and a mortality rate ranging
from 0 to 8 % [4, 7, 16–19, 21–26]. These concerns are
reflected in numerous international guidelines, which limit
recommendations for liver resection to small tumors [2]. In
contrast, recent Japanese guidelines used physiological
criteria and liver remnant size, rather than tumor size, to
determine the indications for liver resection in HCC [35–
37]. This difference in recommendations stems from the
lack of data and reflects concerns regarding the long-term
results of such aggressive management.
The goal of the present study was to analyze long-term
survival and disease-free survival after liver resection for
giant HCC C 10 cm compared to HCC \ 10 cm in diam-
eter. Our hypothesis was that tumor size may not be the
determinant for survival, thus allowing treatment of giant
HCC by firstline surgery in selected patients.
Patients and methods
From 1 January 1997 to 31 December 2009, 311 consec-
utive patients with HCC were admitted to the Department
of Digestive Surgery at the University Hospital of Lau-
sanne, Switzerland. Of these 311 patients, 114 underwent
liver resection with curative intent and constituted the
study population (Fig. 1). All patients had a confirmed
histological diagnosis of HCC, none of the fibrolamellar
subtype. Thirteen patients were excluded from the analysis
(2 had mixed tumor HCC–cholangiocarcinoma and 11 had
incomplete data). The remaining 101 patients were cate-
gorized into two groups: patients with tumors less than
10 cm in diameter (small HCC; n = 79) and patients with
tumors larger than 10 cm (giant HCC; n = 22). For the
giant HCC group, all histological findings were reviewed
by an independent senior pathologist.
The preoperative work-up included blood tests, includ-
ing alpha-fetoprotein and determination of values needed
to calculate the CHILD score and the MELD score, dual
radiology modalities (thoracoabdominal computed tomog-
raphy [CT] and liver magnetic resonance imaging [MRI])
with liver volumetry. In addition, the indocyanine green
retention (ICGR) test at 15 min and invasive portal pres-
sure measurement were performed. Percutaneous biopsy
was only considered in lesions with non-HCC-typical
imaging. The management strategy for all patients was
discussed during the weekly multidisciplinary hepatobil-
iary conferences, which included surgeons, radiologists,
gastroenterologists, and pathologists.
Liver resection was the treatment proposed to all
patients with a CHILD score of A or B, a MELD score less
than 9 points, a remnant liver volume of at least 40 %, an
ICGR test of less than 15 % at 15 min, and an invasive
portal pressure of less than 10 mmHg.
After IRB approval from the Ethics Committee (Uni-
versity of Lausanne, Switzerland), an anonymized Excel
database was constructed with patient demographic, oper-
ative data, pathological findings, and early follow-up data.
A retrospective analysis of data was performed. The long-
term outcomes were determined by telephone interviews
with the attending physicians.
The primary endpoint was overall five-year survival, and
the secondary endpoints were five-year disease-free sur-
vival, recurrence rate, perioperative mortality at 30 days,
surgical complication rate, and reintervention rate.
Statistical analyses were performed with STATA soft-
ware (Statacorp LP, College Station, TX) using Student’s
t test for categorical data, the Mann–Whitney U test for
continuous data, and the Kaplan–Meier or log-rank test for
survival analysis. The results were expressed as median
and range. The cut-off for statistically significant outcome
was a p value less than 0.05.
Results
Population characteristics and perioperative data
The demographic, histological, and operative data of the
two groups are presented in Table 1. The two groups were
homogeneously distributed in terms of age and preopera-
tive American Society of Anesthesiologists (ASA) scores.
There were significantly more patients with cirrhosis in the
group with small HCC (77 vs. 41 %; p = 0.0013). In this
group, four patients presented with Child–Pugh class B
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cirrhosis compared to none in the giant HCC group, where
all patients presenting with cirrhosis were Child–Pugh class
A. The cirrhosis etiologies were not different between the
two groups apart from non-alcoholic non-viral causes
(primary biliary cirrhosis and hemochromatosis), which
were found more frequently in the small HCC group. The
incidence of non-cirrhotic fibrotic liver disease did not
differ statistically between the two populations.
The median number of liver segments resected per
patient was statistically lower in the group with small HCC
(3 vs. 4; p = 0.005), as was the rate of major hepatectomy,
defined as more than three segments (51 vs. 76 %;
p = 0.03). Despite the differences in this feature of the
operations, the operative time and the time of the Pringle
maneuver were similar. After histological examination, the
rate of R0 resection—defined as the absence of tumor in
contact with the resection plane—was comparable in the
two groups. In terms of staging, no differences were found
between the small and giant HCC groups when comparing
the grade of differentiation, the positive lymph node rate,
and the rate of vascular invasion (microscopic or macro-
scopic). The median follow-up time was also similar in the
two populations (24 vs. 25 months; p = 0.16).
The follow-up data, and the immediate and long term
postoperative data are presented in Table 2.
Immediate postoperative data
The 30-day mortality was not significantly different
between the small and giant HCC groups (7 vs. 0 %;
p = 0.14), but there was higher postoperative morbidity in
the small HCC group (50 vs. 23 %; p = 0.02). Liver-
related complications accounted for 57 % in the small
HCC group and 40 % in the giant HCC group.
Survival
Results of the Kaplan–Meier analysis for overall survival
are presented in Fig. 2. Both median survival (24 vs.
27 months; p = 0.0085) and overall 5-year survival (21 vs.
45 %; p = 0.04) were significantly poorer in the small
HCC group than in the giant HCC group.
Recurrence
Results of the Kaplan–Meier analysis for disease-free
survival are presented in Fig. 3. The median disease-free
survival for the two groups was not significantly different
(10 vs. 15 months; p = 0.47); as was the 5-year disease-
free survival (14 vs. 27 %; p = 0.06). The recurrence rate
was identical in the two groups (47 % for the small HCC
Fig. 1 Study flowchart
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and 45 % for the giant HCC group; p = 0.82). In the group
with small HCC, 10 % of recurrences were local, 41 %
were hepatic recurrences at other locations, and 49 % were
systemic recurrences (distant lymph nodes, lung, bone, and
brain). In the group with giant HCC, 10 % of recurrences
were local, 10 % were hepatic, and 80 % were systemic
Table 1 Demographic, histological, and operative data for patients with small hepatocellular carcinoma and giant HCC
Small HCC (n = 79) Giant HCC (n = 22) p Value
Age, years (range) 67 (21–85) 72 (36–88) 0.14
ASA score 3 3 0.85
Cirrhosis, n (%) 61 (77) 9 (41) 0.0013*
Fibrosis, n (%) 6 (7) 3 (14) 0.46
Child-Pugh class, n (%)
A 75 (95) 22 (100) 0.08
B 4 (5) 0 (0) 0.04*
C 0 (0) 0 (0) –
Etiology of cirrhosis, proportion (%)
Alcoholic 33/61 (54) 3/9 (33) 0.29
Hepatitis C virus 13/61 (21) 2/9 (22) 0.78
Hepatitis B virus 10/61 (16) 4/9 (45) 0.16
Other 5/61 (9) 0/9 (0) 0.02*
Alpha fetoprotein (U/l) 1921 (5–500500) 2040 (2–170000) 0.30
Segments resected, n (range) 3 (1–5) 4 (1–6) 0.005*
Major hepatectomy, n (%) 40 (51) 17 (76) 0.03*
Operative time (min) 199 215 0.31
Pringle maneuver, cumulative min 30 31 0.71
R0 resection, n (%) 77 (97) 21 (95) 0.08
Tumor size, cm (%) 4.9 (1–9) 13.5 (10–21) –
Tumor differentiation, n (%)
Well 38 (48) 7 (33) 0.40
Moderate 29 (37) 9 (40) 0.42
Poor 12 (15) 6 (27) 0.19
Positive lymph nodes, n (%) 1 (1) 0 (0) 0.72
Vascular invasion by histology, n (%) 13 (16) 2 (9) 0.33
ASA American Society of Anesthesiologists
* Statistically significant p \ 0.05
Table 2 Patient outcomes
Outcome Small HCC
(n = 79)
Giant HCC
(n = 22)
p Value
Follow-up, months
(range)
24 (1–186) 25 (2–164) 0.16
Median survival, months
(range)
24 (2–186) 27 (6–164) 0.0085*
5-Year survival (%) 21 45 0.04*
5-Year disease-free
survival (%)
14 27 0.06
Recurrence, n (%) 37 (47) 10 (45) 0.82
Median recurrence time,
months (range)
15 (3–60) 10 (5–34) 0.47
30-Day mortality, n (%) 6 (7) 0 (0) 0.14
Complication rate, n (%) 40 (50) 5 (23) 0.02*
* p \ 0.05
Fig. 2 Overall survival for giant hepatocellular carcinoma (HCC)
versus small HCC (Kaplan–Meier analysis)
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recurrences (distant lymph nodes, lung). In patients with
small HCC, 62 % of the recurrences were treated with
interventional radiology (RFA or TACE), and 22 %
underwent reoperation. In the group with giant HCC, the
corresponding figures were 20 and 20 % for these inter-
ventions, respectively.
Discussion
Our results suggest that there is no outcome difference in
surgery for giant HCC compared to smaller HCC, even if
more complex surgery was performed in giant HCC.
In the present comparative retrospective study, we
observed that overall survival, disease-free survival, and
recurrence rates were similar after resection of giant HCC
and resection of smaller lesions. This result strongly sug-
gests that liver resection is an appropriate option for
treating even very large lesions, as observed in other sur-
gical series [4–26]. In giant HCC, surgery should probably
be considered as firstline therapy, provided sufficient
physiological liver reserves are available. Our results were
concordant with those of Shah et al. [18] and Wang et al.
[19], with 5-year survival rates reported to be as high as
50 %. However, it must be emphasized that the literature
on this topic is somewhat confusing, with contradictory
reports and some 5-year survival rates lower than 25 %
[16, 20, 25].
In our own comparison, we observed that survival was
significantly better in the giant HCC group. This is prob-
ably because our patient population in the giant HCC group
included fewer patients with cirrhosis and no patients with
CHILD B disease. Because of the limited sample size, we
did not specifically analyze prognostic factors after resec-
tion of giant lesions, but, as observed in many other series
[4, 19, 20, 22], the presence of cirrhosis seems to influence
negatively overall survival, regardless of the lesion size.
Having said that, this study was limited by the small
sample size and the retrospective design, but this has been
the case for the majority of other reports on giant HCC, and
these limitations seem difficult to overcome, especially
today, as primary liver resection is used less frequently in
the management of HCC. However, with OLT and inter-
ventional radiology for small lesions, it seems that the
number of patients with giant HCC referred for surgical
consultation may be increasing, making understanding of
such tumors more and more critical.
Another potential bias is the surgical nature of the
present series, including good patient selection. Consider-
ing the small liver remnant, surgeons could have been
negatively influenced, proposing interventions in patients
who had a better functional reserve. Bearing in mind that
the management strategy was proposed by a multidisci-
plinary board, it can be considered that this bias was
minimized and that patient selection was adequate. Finally,
patients with giant HCC may have had less aggressive
tumors, as patients with advanced disease (bilateral
involvement, extrahepatic disease, etc.) are less likely to be
referred for surgical treatment. In addition, it is obvious
that we did not compare our results to other treatment
modalities like RFA or TACE, because of a lack of data
and because these approaches have not been used to treat
tumors larger than 10 cm in our center.
As in other studies [35–37], our results suggest that
functional reserve of the remnant liver parenchyma, more
than size of the lesion, may be important in patient selec-
tion for surgical resection. To assess and improve selection
criteria, our patients underwent an extensive preoperative
work-up that included indocyanine green retention time,
invasive portal vein pressure, and liver volumetric
evaluation.
To further improve the management of giant HCC, more
information about tumor biology and histology should be
obtained. Key points like differentiation grade and the
presence of vascular invasion have been reported to be
associated with poor prognosis [3–5, 7, 15–18, 20–23, 26].
Interestingly however, we did not observe any differences
between our two populations. This point is of importance,
because the assumed aggressiveness of large HCC tumors
represents for some investigators a clear limitation to sur-
gery [38], which was not confirmed by our observations.
In conclusion, our results suggest that liver resection in
the treatment of HCC larger than 10 cm is the best avail-
able therapeutic option in selected patients. A radical sur-
gical approach may achieve good long-term survival and
acceptable disease-free survival comparable to treatment of
smaller lesions.
Fig. 3 Disease-free survival for giant HCC versus small HCC
(Kaplan–Meier analysis)
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